Skip to content

US · NUWE · MEDICAL - DEVICES

Nuwellis, Inc. (NUWE) intrinsic value and stock valuation

$3.41as of 2026-11-21 · Mkt cap 157.66K

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nuwellis, Inc. DCF and intrinsic value

InvestorsCraft values NUWE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NUWE’s statements →

Nuwellis, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Eden Prairie, MN 55344 nuwellis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$8.27M+2.1% 5y CAGRd
20112025
Net income
-$-17.52M
20112025
Free cash flow
-$-10.9M
20112025
Total equity
$2.62M-30.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$8.27M$8.74M$8.86M$8.54M$7.92M
Operating income-$-11.11M-$-10.99M-$-17.63M-$-17.17M-$-19.53M
Net income-$-17.52M-$-11.16M-$-20.21M-$-14.53M-$-19.55M
EPSd-$-87.6M-$-279M———
Operating cash flow-$-10.81M-$-9.59M-$-17.94M-$-15.15M-$-17.84M
Capital expenditure-$-90K-$-60K-$-250K-$-120K-$-220K
Free cash flow-$-10.9M-$-9.65M-$-18.18M-$-15.27M-$-18.06M
Total assets$6.12M$9.86M$9.77M$24.7M$30.4M
Total debt$330K$550K$760K$980K$1.18M
Net debt-$-760K-$-4.55M-$-3.04M-$-16.75M-$-7.57M
Total equity$2.62M$6.53M$3.21M$12.4M$26M
Cash and short-term investments$1.08M$5.09M$3.8M$18.3M$24.2M
Income statement
20252024202320222021
Revenue$8.27M$8.74M$8.86M$8.54M$7.92M
Cost of revenue$3.15M$2.91M$3.88M$3.79M$3.43M
Gross profit$5.12M$5.83M$4.98M$4.75M$4.49M
Research and development expenses$2.71M$3.21M$5.42M$4.34M$4.98M
Selling, general and administrative expenses$13.5M$0.00$17.2M$17.6M$19M
Other expenses$0.00$13.6M$0.00$70K$0.00
Operating expenses$16.2M$16.8M$22.6M$21.9M$24M
Cost and expenses$19.4M$19.7M$26.5M$25.7M$27.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$10.6M$5.61M$3.48M$9.25M$0.00
Depreciation and amortization$420K$310K$360K$370K$490K
Ebitda-$-6.55M-$-10.53M-$-16.36M-$-4.9M-$-19.06M
Operating income-$-11.11M-$-10.99M-$-17.63M-$-17.17M-$-19.53M
Total other income/expenses, net-$-6.41M-$-170K-$-2.57M$2.65M-$-20K
Income before tax-$-17.52M-$-11.16M-$-20.2M-$-14.52M-$-19.55M
Income tax expense$10K$10K$10K$10K$10K
Net income-$-17.52M-$-11.16M-$-20.21M-$-14.53M-$-19.55M
Weighted average shares outstanding$200K$40K$0.00$0.00$0.00
Weighted average diluted shares outstanding$200K$40K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$1.08M$5.09M$3.8M$18.3M$24.2M
Net receivables$1.49M$1.73M$1.95M$1.41M$750K
Inventory$1.91M$1.72M$2M$2.66M$2.84M
Total current assets$5.19M$8.86M$8.21M$22.8M$28.1M
Property, plant and equipment, net$660K$990K$1.44M$1.88M$2.27M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$930K$1.01M$1.56M$1.9M$2.29M
Total assets$6.12M$9.86M$9.77M$24.7M$30.4M
Accounts payable$1.98M$1.64M$2.38M$2.25M$1.41M
Short-term debt$260K$240K$220K$220K$190K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.03M$2.56M$3.17M$4.69M$3.31M
Long-term debt$70K$310K$540K$760K$980K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$460K$780K$3.39M$7.63M$1.16M
Capital lease obligations$70K$550K$540K$980K$1.18M
Total liabilities$3.49M$3.33M$6.56M$12.3M$4.47M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-316.31M-$-298.79M-$-287.63M-$-267.42M-$-252.89M
Accumulated other comprehensive income (loss)$10K-$-50K-$-30K$40K-$-40K
Total equity$2.62M$6.53M$3.21M$12.4M$26M
Total investments$0.00$0.00$0.00$570K$15.5M
Total debt$330K$550K$760K$980K$1.18M
Net debt-$-760K-$-4.55M-$-3.04M-$-16.75M-$-7.57M
Cash flow statement
20252024202320222021
Net income-$-17.52M-$-11.16M-$-20.21M-$-14.53M-$-19.55M
Depreciation and amortization$420K$310K$360K$370K$490K
Stock-based compensation$130K$480K$670K$860K$1.31M
Change in working capital-$-250K-$-300K-$-1.42M$600K-$-100K
Accounts receivable$230K$220K-$-550K-$-660K$150K
Inventory-$-190K$280K$700K$140K-$-140K
Accounts payable$410K$0.00-$-1.5M$0.00$0.00
Net cash provided by operating activities-$-10.81M-$-9.59M-$-17.94M-$-15.15M-$-17.84M
Investments in property, plant and equipment-$-90K-$-60K-$-150K-$-120K-$-220K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-90K-$-60K$330K$14.7M-$-15.72M
Common stock issued$6.94M$7.93M$2.11M$9.45M$27.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.94M$11M$3.68M$9.42M$27.9M
Net change in cash-$-3.9M$1.29M-$-13.94M$8.99M-$-5.7M
Cash at end of period$1.19M$5.09M$3.8M$17.7M$8.74M
Operating cash flow-$-10.81M-$-9.59M-$-17.94M-$-15.15M-$-17.84M
Capital expenditure-$-90K-$-60K-$-250K-$-120K-$-220K
Free cash flow-$-10.9M-$-9.65M-$-18.18M-$-15.27M-$-18.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nuwellis, Inc.

        Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

        CEO
        Michael McCormick
        Employees
        38
        Beta
        0.30

        Explore

        Frequently asked questions

        What is the intrinsic value of Nuwellis, Inc. (NUWE)?

        Nuwellis, Inc. (NUWE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NUWE undervalued?

        NUWE trades at a price of $3.41 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.